Pick Topic
Review Topic
List Experts
Examine Expert
Save Expert
  Site Guide ··   
Coronary Artery Disease: HELP
Articles by Henrique Barbosa Ribeiro
Based on 6 articles published since 2010
(Why 6 articles?)

Between 2010 and 2020, Henrique B. Ribeiro wrote the following 6 articles about Coronary Artery Disease.
+ Citations + Abstracts
1 Editorial Seeking actual benchmarks in acute coronary syndromes for European countries: insights from the EURHOBOP registry. 2014

Ribeiro, Henrique B / Lemos, Pedro A. ·Department of Medicine, Quebec Heart & Lung Institute, Laval University, Quebec City, Quebec, Canada. · Department of Interventional Cardiology, Heart Institute (InCor), University of São Paulo Medical School, Sao Paulo, Brazil. ·Heart · Pubmed #24829366.

ABSTRACT: -- No abstract --

2 Review Coronary obstruction following transcatheter aortic valve implantation: a systematic review. 2013

Ribeiro, Henrique Barbosa / Nombela-Franco, Luis / Urena, Marina / Mok, Michael / Pasian, Sergio / Doyle, Daniel / DeLarochellière, Robert / Côté, Mélanie / Laflamme, Louis / DeLarochellière, Hugo / Allende, Ricardo / Dumont, Eric / Rodés-Cabau, Josep. ·Quebec Heart and Lung Institute, Laval University, Quebec City, Quebec, Canada. ·JACC Cardiovasc Interv · Pubmed #23602458.

ABSTRACT: OBJECTIVES: This study sought to evaluate, through a systematic review of the published data, the main baseline characteristics, management, and clinical outcomes of patients suffering coronary obstruction as a complication of transcatheter aortic valve implantation (TAVI). BACKGROUND: Very few data exist on coronary obstruction after TAVI. METHODS: Studies published between 2002 and 2012, with regard to coronary obstruction as a complication of TAVI, were identified with a systematic electronic search. Only the studies reporting data on the main baseline and procedural characteristics, management of the complication, and clinical outcomes were analyzed. RESULTS: A total of 18 publications describing 24 patients were identified. Most (83%) patients were women, with a mean age of 83 ± 7 years and a mean logistic European System for Cardiac Operative Risk Evaluation score of 25.1 ± 12.0%. Mean left coronary artery (LCA) ostium height and aortic root width were 10.3 ± 1.6 mm and 27.8 ± 2.8 mm, respectively. Most patients (88%) had received a balloon-expandable valve, and coronary obstruction occurred more frequently in the LCA (88%). Percutaneous coronary intervention was attempted in 23 cases (95.8%) and was successful in all but 2 patients (91.3%). At 30-day follow-up, there were no cases of stent thrombosis or repeat revascularization, and the mortality rate was 8.3%. CONCLUSIONS: Reported cases of coronary obstruction after TAVI occurred more frequently in women, in patients receiving a balloon-expandable valve, and the LCA was the most commonly involved artery. Percutaneous coronary intervention was a feasible and successful treatment in most cases. Continuous efforts should be made to identify the factors associated with this life-threatening complication to implement the appropriate measures for its prevention.

3 Review Real-world use of drug-eluting stents: the importance of registries. 2010

Ribeiro, Expedito E / Ribeiro, Henrique Barbosa. ·Instituto do Coração, Faculdade de Medicina, Universidade de São Paulo, São Paulo, SP, Brasil. expribeiro@terra.com.br ·Arq Bras Cardiol · Pubmed #20694400.

ABSTRACT: Over the last decades the efficacy and safety of bare metal (BMS) and drug eluting stents (DES) have been demonstrated in many different clinical scenarios, leading to their use in more than 75% of the procedures worldwide. Compared to BMS, DES have shown lower rates of angiographic restenosis and target-vessel revascularization. This benefit was initially demonstrated in trials that excluded patients with more complex lesions, such as those with larger or smaller vessels, chronic total occlusions, bifurcation lesions, stent restenosis, long lesions and left main coronary artery disease. This real-world population has been recently evaluated in many registries and meta-analyses that are reviewed herein.

4 Article Prognostic value of dobutamine stress myocardial perfusion echocardiography in patients with known or suspected coronary artery disease and normal left ventricular function. 2017

Mattoso, Angele A A / Tsutsui, Jeane M / Kowatsch, Ingrid / Cruz, Vitória Y L / Sbano, João C N / Ribeiro, Henrique B / Kalil Filho, Roberto / Porter, Thomas R / Mathias, Wilson. ·Heart Institute (InCor), University of São Paulo Medical School, São Paulo, Brazil. · University of Nebraska Medical Center, Omaha, United States of America. ·PLoS One · Pubmed #28234978.

ABSTRACT: OBJECTIVE: We sought to determine the prognostic value of qualitative and quantitative analysis obtained by real-time myocardial perfusion echocardiography (RTMPE) in patients with known or suspected coronary artery disease (CAD). BACKGROUND: Quantification of myocardial blood flow reserve (MBFR) in patients with CAD using RTMPE has been demonstrated to further improve accuracy over the analysis of wall motion (WM) and qualitative analysis of myocardial perfusion (QMP). METHODS: From March 2003 to December 2008, we prospectively studied 168 patients with normal left ventricular function (LVF) who underwent dobutamine stress RTMPE. The replenishment velocity reserve (β) and MBFR were derived from RTMPE. Acute coronary events were: cardiac death, myocardial infarction and unstable angina with need for urgent coronary revascularization. RESULTS: During a median follow-up of 34 months (5 days to 6.9 years), 17 acute coronary events occurred. Abnormal β reserve in ≥2 coronary territories was the only independent predictor of events hazard ratio (HR) = 21, 95% CI = 4.5-99; p<0.001). Both, abnormal β reserve and MBFR added significant incremental value in predicting events over qualitative analysis of WM and MP (χ2 = 6.6 and χ2 = 24.6, respectively; p = 0.001 and χ2 = 6.6 and χ2 = 15.5, respectively; p = 0.012, respectively). When coronary angiographic data was added to the multivariate analysis model, β reserve remained the only predictor of events with HR of 21.0 (95% CI = 4.5-99); p<0.001. CONCLUSION: Quantitative dobutamine stress RTMPE provides incremental prognostic information over clinical variables, qualitative analysis of WM and MP, and coronary angiography in predicting acute coronary events.

5 Article Outcomes in Patients With Transcatheter Aortic Valve Replacement and Left Main Stenting: The TAVR-LM Registry. 2016

Chakravarty, Tarun / Sharma, Rahul / Abramowitz, Yigal / Kapadia, Samir / Latib, Azeem / Jilaihawi, Hasan / Poddar, Kanhaiya Lal / Giustino, Gennaro / Ribeiro, Henrique B / Tchetche, Didier / Monteil, Benoit / Testa, Luca / Tarantini, Giuseppe / Facchin, Michela / Lefèvre, Thierry / Lindman, Brian R / Hariri, Babak / Patel, Jigar / Takahashi, Nobuyuki / Matar, George / Mirocha, James / Cheng, Wen / Tuzcu, Murat E / Sievert, Horst / Rodés-Cabau, Josep / Colombo, Antonio / Finkelstein, Ariel / Fajadet, Jean / Makkar, Raj R. ·Cedars-Sinai Heart Institute, Los Angeles, California. · Cedars-Sinai Heart Institute, Los Angeles, California; Tel Aviv Medical Center, Tel Aviv, Israel. · Cleveland Clinic, Cleveland, Ohio. · San Raffaele Scientific Institute and EMO-GVM Centro Cuore Columbus, Milan, Italy. · Quebec Heart and Lung Institute, Laval University, Quebec City, Quebec, Canada. · Clinique Pasteur, Toulouse, France. · IRCCS Policlinico San Donato, San Donato Milanese, Milan, Italy. · Department of Cardiac, Thoracic and Vascular Sciences, University of Padova, Padova, Italy. · Hopital Privé Jacques Cartier, Massy, France. · Washington University School of Medicine, St. Louis, Missouri. · CardioVascular Center Frankfurt CVC, Frankfurt, Germany. · Tel Aviv Medical Center, Tel Aviv, Israel. · Cedars-Sinai Heart Institute, Los Angeles, California. Electronic address: makkarr@cshs.org. ·J Am Coll Cardiol · Pubmed #26916485.

ABSTRACT: BACKGROUND: A percutaneous approach with transcatheter aortic valve replacement (TAVR) and percutaneous coronary intervention (PCI) of the left main coronary artery (LM) is frequently used in high-risk patients with coexisting aortic stenosis and LM disease. Outcomes of TAVR plus LM PCI have not been previously reported. OBJECTIVES: The primary objective of the TAVR-LM registry is to evaluate clinical outcomes in patients undergoing TAVR plus LM PCI. METHODS: Clinical, echocardiographic, computed tomographic, and angiographic characteristics were retrospectively collected in 204 patients undergoing TAVR plus LM PCI. In total, 128 matched patient pairs were generated by performing 1:1 case-control matching between 167 patients with pre-existing LM stents undergoing TAVR and 1,188 control patients undergoing TAVR without LM revascularization. RESULTS: One-year mortality (9.4% vs. 10.2%, p = 0.83) was similar between the TAVR plus LM PCI cohort and matched controls. One-year mortality after TAVR plus LM PCI was not different in patients with unprotected compared with protected LMs (7.8% vs. 8.1%, p = 0.88), those undergoing LM PCI within 3 months compared with those with LM PCI greater than 3 months before TAVR (7.4% vs. 8.6%, p = 0.61), and those with ostial versus nonostial LM stents (10.3% vs. 15.6%, p = 0.20). Unplanned LM PCI performed because of TAVR-related coronary complication, compared with planned LM PCI performed for pre-existing LM disease, resulted in increased 30-day (15.8% vs. 3.4%, p = 0.013) and 1-year (21.1% vs. 8.0%, p = 0.071) mortality. CONCLUSIONS: Despite the anatomic proximity of the aortic annulus to the LM, TAVR plus LM PCI is safe and technically feasible, with short- and intermediate-term clinical outcomes comparable with those in patients undergoing TAVR alone. These results suggest that TAVR plus LM PCI is a reasonable option for patients who are at high risk for surgery.

6 Article First-in-man randomised comparison of a novel sirolimus-eluting stent with abluminal biodegradable polymer and thin-strut cobalt-chromium alloy: INSPIRON-I trial. 2014

Ribeiro, Expedito E / Campos, Carlos M / Ribeiro, Henrique B / Lopes, Augusto C / Esper, Rodrigo B / Meirelles, George X / Perin, Marco A / Abizaid, Alexandre / Lemos, Pedro A. ·Department of Interventional Cardiology, Heart Institute-InCor, University of São Paulo, São Paulo, Brazil. ·EuroIntervention · Pubmed #24755382.

ABSTRACT: AIMS: The INSPIRON-I trial is a first-in-man evaluation of the safety and efficacy of the Inspiron drug-eluting stent, a sirolimus-eluting stent with abluminal biodegradable polymer coating and thin cobalt-chromium alloy. METHODS AND RESULTS: This is a randomised, multicentre comparison between Inspiron and a stent with the same metallic structure but without polymer coating or drug elution (Cronus). The primary objective was to evaluate the in-segment late loss (LLL) at six months. Secondary endpoints included percent in-stent obstruction as measured by intravascular ultrasound (IVUS) at six months and major adverse cardiac events (MACE). Fifty-eight patients were enrolled (60 lesions), 39 for Inspiron and 19 for Cronus. Baseline clinical and angiographic characteristics of both groups were similar. At six months, the in-segment LLL was reduced in the Inspiron group compared to the control group (0.19±0.16 mm vs. 0.58±0.4 mm, respectively; p<0.001), as well as the percent neointimal obstruction (7.8±7.1% vs. 26.5±11.4%; p<0.001). At two-year follow-up, incidence of MACE was similar between groups (7.9 vs. 21.1%, respectively; p=0.20), with lower target lesion revascularisation for Inspiron (0 vs. 21.1%, respectively; p=0.01) and no stent thrombosis. CONCLUSIONS: Sirolimus eluted from an abluminal biodegradable polymer on a cobalt-chromium alloy proved effective in reducing restenosis at six months.